BCL6 knockdown or paclitaxel treatment modestly reduced MDA‐MB‐231 tumor growth; however, the combination of BCL6 knockdown and paclitaxel resulted in significant reduction in tumor volumes (Fig. 3B) and weights (Fig. 3C). Here, BCL6 is linked to neoplasm.